Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

46 results about "Pathway analysis" patented technology

In bioinformatics research, pathway analysis software is used to identify related proteins within a pathway or building pathway de novo from the proteins of interest. This is helpful when studying differential expression of a gene in a disease or analyzing any omics dataset with a large number of proteins. By examining the changes in gene expression in a pathway, its biological causes can be explored. Pathway is the term from molecular biology which depicts an artificial simplified model of a process within a cell or tissue. A typical pathway model starts with an extracellular signaling molecule that activates a specific receptor, thus triggering a chain of protein-protein or protein-small molecule interactions. Pathway analysis helps to understand or interpret omics data from the point of view of canonical prior knowledge structured in the form of pathways diagrams. It allows finding distinct cell processes (Cellular processes), diseases or signaling pathways that are statistically associated with selection of differentially expressed genes between two samples. Often but erroneously pathway analysis is used as synonym for network analysis (functional enrichment analysis and gene set analysis).

SNP (Single Nucleotide Polymorphism) mutation site associated with turbot blackening, molecular marker and application

The invention provides an SNP (Single Nucleotide Polymorphism) mutation site associated with turbot blackening, a molecular marker and application, and belongs to the technical field of molecular markers. According to the SNP locus related to turbot blackening, the SNP locus related to turbot blackening is found through pathway analysis, SNP locus screening, SNP locus typing and SNP locus screening related to turbot non-eye side body color blackening, the SNP locus is located on a gene tyrosinase-related protein 1b, a base G at the 835bp position is mutated into A, aspartic acid can be changed into asparagine, and the non-eye side of turbot is not prone to blackening. When scophthalmus maximus breeding is carried out, the breeding scophthalmus maximus can be subjected to pre-breeding molecular screening by using the SNP site associated with the body color blackening of the non-eye side of the scophthalmus maximus, so that the occurrence rate of the non-eye side blackening of the progeny of the scophthalmus maximus is reduced from germplasm, and the blackening phenomenon in the breeding process of the scophthalmus maximus is reduced.
Owner:SHANGHAI OCEAN UNIV

Single-cell transcriptome data-assisted AD analysis and classification method

The invention relates to a single cell transcriptome data assisted AD analysis and classification method. The method comprises the following steps: acquiring a brain tissue sample from an AD patient and an age-matched healthy control, and treating the brain tissue by using a cell separation technology; then, sequencing the separated single cells by adopting a high-throughput single cell transcriptome sequencing platform, performing data quality control, and removing low-quality cells and low-expression genes; performing standardization processing on gene expression data, and eliminating technical deviation among different samples by using Log2 conversion and Z-score standardization; dimensionality reduction processing is carried out on the high-dimensional data by using dimensionality reduction algorithms of principal component analysis (PCA), t-SNE and UMAP; differential expression including DESeq2 and EdgeR is utilized to analyze and identify genes with significant difference between the AD patient and the healthy control; gSEA is adopted for gene set enrichment analysis, KEGG and GO are adopted for pathway analysis, and a key gene pathway and a biological process related to AD are determined; and inputting single cell transcriptome data of a new sample into the trained classification model, and performing AD classification prediction.
Owner:JINHUA VOCATIONAL TECH COLLEGE

Drug effect prediction method for drug research and development

InactiveCN120199516ADrug referencesSequence analysisPathway analysisChemical compound
The invention discloses a drug effect prediction method for drug research and development, and relates to the technical field of drug effect analysis, and the method comprises the steps: collecting drug and target data from a plurality of data sources, and carrying out the preprocessing of the drug and target data; and carrying out feature analysis on the basis of the preprocessed drug and target data to obtain a comprehensive feature sequence, carrying out gene and pathway analysis on a disease applied by the drug, carrying out disease feature coding, and then modeling a disease background. According to the method, drug-target pairs with potential drug effects can be rapidly screened in the early stage of drug research and development through drug effect prediction, further research on a large number of invalid compounds is avoided, time and resources are saved, and then, the interaction strength between the drug and the target is predicted through the model, so that the drug effect is improved. And comprehensive analysis is carried out in combination with a disease background, so that potential drug candidate molecules can be identified more accurately, and the research and development cycle is further shortened.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Biological signal transduction pathway analysis method based on protein network

PendingCN120126541ABiostatisticsMachine learningPathway analysisBiological signaling
The invention provides a biological signal transduction pathway analysis method based on a protein network, which comprises the following steps: acquiring omics data, and preprocessing the omics data to obtain preprocessed omics data; constructing a cell specific protein interaction network according to the preprocessing omics data; extracting topological structure characteristics from the cell specific protein interaction network; obtaining a signal transduction path according to the topological structure features and a network topological feature prediction model; and obtaining a signal transduction path analysis result according to the signal transduction path. According to the method, multi-omics data and a machine learning algorithm are combined, a complex signal transduction mechanism can be revealed from a global perspective, and the prediction accuracy is improved.
Owner:CHONGQING RUANJIANG TURING ARTIFICIAL INTELLIGENCE TECH CO LTD

Multi-omics deep learning based colorectal cancer liver metastasis detection method and system

The application discloses a kind of based on multi-omics deep learning colorectal cancer liver metastasis detection method and system, comprising: extracting the feature gene group with CRC transfer-metabolic dual function, and construct CRC transfer risk prediction model foundation, based on analysis CRC transfer risk probability to screen the molecular marker with CRC transfer nature and CRLM specific characteristics as initial candidate biomarker;Meanwhile, from the metabolome to obtain the differential expression metabolite corresponding to CRLM patient sample and LCRC patient sample metabolome, and the enrichment pathway analysis of transcriptome and metabolome is combined to construct CRLM multi-layer core metabolic network, for the screening core biomarker of colorectal cancer liver metastasis accurate detection in accordance with, entire method can effectively screen the biomarker for detecting colorectal cancer liver metastasis.
Owner:ZHEJIANG UNIV

Method for efficiently extracting active ingredients of traditional Chinese medicine based on modern biotechnology and application of method

The invention provides an innovative method for extracting active ingredients of traditional Chinese medicines, which integrates the modern biotechnology and aims at improving the extraction efficiency and purity and reducing the loss of the active ingredients at the same time. The core technology comprises enzyme-method-assisted extraction and efficient catalysis of release of active components by using a specific enzyme modified by genetic engineering; a supercritical fluid extraction and membrane separation technology is adopted, so that high-efficiency preliminary extraction and accurate separation are realized; a microwave-assisted extraction and dynamic countercurrent technology is adopted, so that the continuous extraction efficiency is improved; the molecular imprinting technology is used for selective adsorption and enrichment of target components; biosynthetic pathway analysis provides theoretical support for extraction optimization; the release and stability of active ingredients are enhanced by tissue crushing and heating-free extraction technologies; and a high-speed counter-current chromatography separation technology is adopted to finish fine separation of active components. The method has the advantages of being simple and convenient to operate, high in efficiency, good in purity, wide in application range and the like, and a brand new efficient technical scheme is provided for extraction of active ingredients of traditional Chinese medicine.
Owner:HENAN UNIV OF CHINESE MEDICINE

Colorectal cancer liver metastasis detection method and system based on multi-omics deep learning

The invention discloses a colorectal cancer liver metastasis detection method and system based on multi-omics deep learning, and the method comprises the steps: extracting a characteristic gene group with CRC metastasis-metabolism dual functions, and on the basis of constructing a CRC metastasis risk prediction model, screening molecular markers with CRC metastasis general and CRLM specific characteristics based on the analysis of CRC metastasis risk probability, the biomarker is used as an initial candidate biomarker; meanwhile, a CRLM patient sample and differential expression metabolites corresponding to an LCRC patient sample metabolome are obtained from a metabolome, and a CRLM multilayer core metabolic network is constructed in combination with enrichment pathway analysis of a transcriptome and the metabolome, so that core biomarkers are screened for accurate detection of colorectal cancer liver metastasis; the whole method can effectively screen the biomarker beneficial to detection of colorectal cancer liver metastasis.
Owner:ZHEJIANG UNIV

Maize kernel development regulatory gene ZmGWT1a, its encoded protein, SNP sites, functional markers and their applications

The present invention discloses a corn kernel development regulating gene ZmGWT1a , its encoded protein, SNP site, functional marker and its application. The present invention applies to utilize the natural mutant of corn kernels found in the process of corn field breeding and selection gwt1a Cloning of key genes affecting GPI synthesis ZmGWT1a , which encodes an acyltransferase in step 4 of the glycophosphatidylinositol (GPI) biosynthesis pathway; ZmGWT1a Genes regulate the development of corn embryo and endosperm, affecting the accumulation of grain storage substances, but not affecting the normal growth and development of the plant, which is of great value in increasing corn yield; ZmGWT1a The identification of excellent haplotypes and analysis of their utilization pathways provide technical support and excellent germplasm resources for the utilization of the gene. The use of the gene and functional markers disclosed in the present invention application can facilitate the creation of high-yield breeding materials for corn, shorten the breeding cycle of new crop varieties, reduce breeding costs, and improve breeding efficiency.
Owner:HENAN AGRICULTURAL UNIVERSITY

A disease treatment target discovery and drug prediction method based on multi-omics network and deep learning model

PendingCN122314073APathway analysisNeural network nn
This invention relates to a method for disease therapeutic target discovery and drug prediction based on multi-omics networks and deep learning models, belonging to the interdisciplinary field of bioinformatics and artificial intelligence drug discovery. The method includes: integrating genomic expression profiles and common molecular interaction data from disease and control groups to construct a candidate whole-genome network; refining the network based on expression profile data through systematic modeling and the AIC criterion to obtain the real molecular interaction network; extracting the core network using the master network projection method and identifying key targets through pathway analysis; predicting candidate drugs interacting with the targets using a pre-trained deep neural network model; and finally screening potential therapeutic drugs based on multi-dimensional criteria such as regulatory ability, sensitivity, and toxicity. This invention achieves a complete integration from disease mechanism analysis to drug prediction, and is particularly suitable for complex diseases such as atopic dermatitis. It can systematically discover precise targets and efficiently predict repositionable drugs, significantly improving R&D efficiency.
Owner:NINGBO CHSIRGA METAL PROD CO LTD

Method for analyzing angiogenesis promoting mechanism of qi-regulating and blood-activating dropping pills based on network pharmacology

The invention relates to the technical field of traditional Chinese medicine compound action mechanism research, and discloses a method for analyzing an angiogenesis promoting mechanism of a qi-regulating and blood-activating dropping pill based on network pharmacology, and the method comprises the following steps: S1, blood-entering component identification: identifying blood-entering components and metabolites of the qi-regulating and blood-activating dropping pill to obtain structure information of 18 blood-entering components and metabolites; s2, target spot prediction and screening; s3, core target point analysis; s4, network construction and analysis: constructing a drug-in-blood component-target-disease network, and determining a core in-blood component of which the degree value is greater than the average value through topological analysis; s5, function enrichment and pathway analysis: performing GO function enrichment analysis and KEGG signal pathway analysis on the target spots intersected in S2, and determining a core pathway for promoting angiogenesis; s6, carrying out molecular docking verification; and S7, in-vitro activity verification. Through integration of network pharmacology, molecular docking and in-vitro experiment verification, the action mechanism of the qi-regulating and blood-activating dropping pill for promoting angiogenesis is systematically disclosed.
Owner:CENT SOUTH UNIV

Multi-omics-based Changbai Mountain Chinese bee honey characteristic component analysis method

The invention relates to the technical field of honey identification, in particular to a multi-omics-based Changbai Mountain Chinese bee honey characteristic component analysis method. According to the method, mass spectrometric detection is carried out on the Changbai Mountain apis cerana honey and the reference substance honey, qualitative and quantitative analysis is carried out on metabolites and proteins of the honey, metabonomics and proteomics information is obtained, and metabonomics and proteomics difference information of the Changbai Mountain apis cerana honey and the reference substance honey is obtained; the method comprises the following steps: carrying out functional annotation on the Chinese bee honey, finding out KEGG pathways annotated by two groups of schools by utilizing KEGG database pathway analysis, carrying out expression correlation analysis and O2PLS analysis on the KEGG pathways annotated by the two groups of schools, and screening characteristic components of the Chinese bee honey in the Changbai Mountain; potential characteristic substances of the Changbai Mountain apis cerana honey are obtained through screening, and a scientific basis is further provided for origin traceability and quality identification of the apis cerana honey.
Owner:JILIN AGRI SCI & TECH COLLEGE

Method for analyzing target spot of cyclosporine for treating aplastic anemia

The invention relates to the technical field of bioinformatics, and provides an analysis method for treating aplastic anemia (AA) targets by cyclosporine, which comprises the following steps: collecting plasma samples from a preliminary diagnosis patient, a disease stable period patient and a healthy control group; the method comprises the following steps: based on a DIA quantitative proteomics method, analyzing proteins in a plasma sample by adopting a liquid chromatography-mass spectrometer (LC-MS) method, and screening differential expression proteins; carrying out enrichment analysis and pathway analysis on the differential expression protein; verifying the expression levels of the differential expression proteins in different groups by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method to obtain key differential expression proteins; a molecular docking technology is adopted to verify the binding capacity of cyclosporine and the differential expression protein, and the potential of the key differential expression protein as a therapeutic target is determined. Different differential proteins of AA patients and healthy people before and after treatment are successfully obtained, an experimental basis is provided for exploring a mechanism for treating AA by cyclosporine, and possibility is provided for searching a new treatment target.
Owner:YIXING PEOPLES HOSPITAL

Pathway analysis device, pathway analysis method, and pathway analysis program

PendingEP4509795A1Medical simulationData visualisationPathway analysisData mining
The partial common path detection unit 12 configured to detect a common part exclusively in a portion between a start point and an end point of a path among a plurality of disease pathways representing, as a route map, an intermolecular interaction of related molecules with respect to a disease for each of a plurality of diseases related to state changes, and the common difference information provision unit 13 configured to provide information on a detected partial common path or a molecule included in the partial common path and a non-partial common path other than the partial common path or a molecule included in the non-partial common path in a state where whether the partial common path is related or the non-partial common path is related is distinguishable are provided, and a change in pathway due to the state change of the disease can be understood by providing information so that which part is common and which part is not common between a start point and an end point of a path can be understood in a relationship between a disease pathway related to a disease before state change and a disease pathway related to the disease after the state change.
Owner:FRONTEO INC

Gene expression prediction method based on deductive learning and gene knowledge ontology

PendingCN120954499ABiostatisticsBiological modelsPathway analysisRule mining
The invention discloses a gene expression prediction method based on anti-deductive learning and gene knowledge ontology, and aims to solve the problems of large data demand and poor interpretability in a traditional gene expression prediction method. And constructing a gene expression prediction model by combining anti-deductive learning and gene knowledge ontology. Obtaining gene expression data from the public database, and carrying out data preprocessing and importance feature extraction; constructing a structured knowledge graph by using the gene knowledge ontology, and generating a logic rule set through sub-graph extraction and rule mining; an anti-deductive learning framework is adopted to fuse a machine learning module and a knowledge reasoning module, and prediction accuracy and logic consistency are improved through iterative optimization; through false label correction and label-free data utilization, the performance of the model under a small sample condition is enhanced. According to the method, the accuracy and interpretability of gene expression prediction are remarkably improved, efficient support can be provided for biological experiment design, gene regulation pathway analysis and the like, and the method has a wide application prospect.
Owner:王俊童 +1

Pathway analysis device, pathway analysis method, and pathway analysis program

PCT designated stage expiredWO2025004167A1Medical simulationData visualisationPathway analysiscomputer science
The present invention comprises: a partially common path detection unit 12 that detects a portion common in only a part of a path from a start point to an end point among a plurality of disease pathways that represent a molecular interaction among disease-related molecules as a path diagram for each of a plurality of diseases related to a state change; and a common difference information providing unit 13 that executes information provision of the detected partially common path or a molecule included in this partially common path and a non-partially common path other than the partially common path or a molecule included in this non-partially common path in a state in which the provided information can be identified as information relating to the partially common path or information relating to the non-partially common path. By providing information such that, in a relationship between a disease pathway related to a disease before a state change and a disease pathway related to the disease after the state change, a common part of the paths from start points to end points and non-common parts of the paths are recognizable, the change in pathway caused by the state change of the disease can be recognized.
Owner:FRONTEO INC

A polypeptide with methylation function at n-position of a genus amaryllidaceae alkaloid compound, and a coding gene and application thereof

PendingCN122104626ABacteriaTransferasesSynthetic biologyPathway analysis
The application provides a polypeptide with N-methylation function of an Amaryllidaceae alkaloid compound, a coding gene and application thereof, and belongs to the technical field of bioengineering. The polypeptide is selected from the following (a) a polypeptide consisting of an amino acid sequence shown in SEQ ID NO. 1; (b) a polypeptide consisting of an amino acid sequence shown in SEQ ID NO. 2. The application provides a new key enzyme element for Amaryllidaceae alkaloid biosynthesis pathway analysis, metabolic engineering modification and synthetic biology research, has important scientific research value and potential industrial application prospect, meanwhile, the technical scheme is complete, the application range is wide, and the stability and anti-avoidance capability of patent protection can be improved.
Owner:NORTHWESTERN POLYTECHNICAL UNIV

A comorbidity mechanism identification method and system based on complement-coagulation axis and ceRNA network

PendingCN122157775ABiostatisticsProteomicsAutoimmune conditionPathway analysis
The application relates to a comorbidity mechanism identification method and system based on a complement-coagulation axis and a ceRNA network, and relates to the technical field of biomedical testing. The method comprises the following steps: integrating transcriptome expression characteristics of different diseases and performing immune pathway analysis, taking the complement-coagulation axis as a breakthrough point, identifying an inflammatory signal module shared by endometriosis and subacute cutaneous type red lupus, and further screening candidate target points with cross expression characteristics and immune regulation functions. At the regulation mechanism level, a circRNA-miRNA-mRNA ternary regulation network containing a circRNA node is constructed to obtain more complete non-coding regulation axis information; meanwhile, a plurality of algorithms are introduced to cooperatively screen and verify an independent data set, a repeatable, verifiable and expandable molecular mechanism mining process is formed, and thus the comorbidity mechanism identification analysis between diseases is realized, and technical support and path reference are provided for comorbidity mechanism research of autoimmune diseases.
Owner:FOSHAN MATERNAL & CHILD HEALTH CARE HOSPITAL

Pathway analysis apparatus, pathway analysis method, and pathway analysis program

ActiveUS20250226112A1Medical simulationData visualisationPathway analysisBioinformatics
The partial common path detection unit 12 configured to detect a common part exclusively in a portion between a start point and an end point of a path among a plurality of disease pathways representing, as a route map, an intermolecular interaction of related molecules with respect to a disease for each of a plurality of diseases related to state changes, and the common difference information provision unit 13 configured to provide information on a detected partial common path or a molecule included in the partial common path and a non-partial common path other than the partial common path or a molecule included in the non-partial common path in a state where whether the partial common path is related or the non-partial common path is related is distinguishable are provided, and a change in pathway due to the state change of the disease can be understood by providing information so that which part is common and which part is not common between a start point and an end point of a path can be understood in a relationship between a disease pathway related to a disease before state change and a disease pathway related to the disease after the state change.
Owner:FRONTEO INC

Identification and use of SHP2 conformational disruptors for cancer treatment

Compounds were identified from SHP2 Protein Conformational Array (PCA) ELISA. These compounds can disrupt SHP2 Higher Order Structure (HOS) in vitro and induce SHP2 degradation in multiple cancer cell lines. The SHP2-KRAS-ERK pathway analysis indicated that these identified compounds could induce inactivation of the active form of ERK, P-ERK. In addition, some of the compounds can induce SHP2 and / or KRAS degradation in multiple cancer cell lines. Cancer cell line testing demonstrated that these compounds identified through SHP2 HOS disruption showed dose-dependent growth inhibition. Since the SHP2-KRAS-ERK pathway plays an important role in cancer development, these compounds can be used as potential cancer treatments.
Owner:WANG XING +1

Urine exposure biomarker of p-hydroxyacetophenone and application of urine exposure biomarker in human body load monitoring

ActiveCN120177673AComponent separationHuman bodyPathway analysis
The invention discloses a urine exposure biomarker of p-hydroxyacetophenone and application of the urine exposure biomarker in human body load monitoring. On the basis of the I / II phase metabolic transformation rule of PHAC, a targeted screening list is formed, the mass spectrum fragment collection efficiency and qualitative analysis capability are enhanced, and full spectrum screening of the urine exposure biomarkers is realized by combining high-resolution mass spectrum data and a fragment ion search system; further simulating and locking potential targets through metabolic site energy, and analyzing accurate molecular structures and metabolic conversion paths of the six PHAC urine exposure biomarkers by utilizing a fragment ion spectrum intelligent matching algorithm; meanwhile, through metabolite peak area semi-quantitative analysis, a noninvasive urine sample is utilized for the first time to determine the PHAC high-sensitivity exposure biomarker capable of monitoring loads in a human body.
Owner:SOUTH CHINA INST OF ENVIRONMENTAL SCI MEP

A Metabolomics Chromatographic Peak Extraction Method Based on Secondary Mass Spectrometry Qualitative Results

ActiveCN117368388BComponent separationPathway analysisPhysical chemistry
This invention discloses a method for extracting metabolomics chromatographic peaks based on secondary mass spectrometry qualitative results. This method starts with secondary mass spectrometry in metabolomics, utilizing the qualitative results from the secondary mass spectrometry in a qualitative library, combined with XCMS (XML Cryptographic Message Syntax) peak extraction results to obtain more comprehensive chromatographic peak information. This invention starts with the secondary mass spectrometry characteristics that contain more mass spectrometry information and have clear chemical meanings, improving the accuracy of chromatographic peak extraction and clarifying the specific biological significance of metabolomics chromatographic peaks. This is beneficial for further discovery of metabolomics differentials, pathway analysis, and interpretation of biological significance. Figure 1 in the accompanying drawings is a flowchart of this invention.
Owner:DALIAN CHEM DATA SOLUTION TECH CO LTD

A bioinformatics-based method for analyzing common targets of the miR-106a-363 cluster

ActiveCN119028450BMedical data miningBiostatisticsPathway analysisImmunity
The present invention relates to the field of bioinformatics and discloses a method for analyzing the common targets of the miR-106a-363 cluster based on bioinformatics, comprising the following steps: correlation analysis between the miR-106-363 cluster and tuberculosis; target gene and pathway analysis of tuberculosis-related members in the miR-106-363 cluster; and verification of the interaction between members of the miR-106-363 cluster and key target genes in tuberculosis infection. The present invention adopts the above-mentioned method to predict the common targets of the miR-106a-363 cluster, locates the potential key targets of the miRNA cluster affecting tuberculosis immunity through literature analysis combined with the prediction results, and verifies the regulatory relationship between the bovine miR-106a-363 cluster and the target genes, revealing its potential role in tuberculosis immunity in dairy cows, and providing a new theoretical basis and research ideas for further research on tuberculosis and anti-tuberculosis gene editing breeding targets.
Owner:NORTHWEST A & F UNIV

Pathway analysis device, pathway analysis method, and pathway analysis program

PCT designated stage expiredWO2025004276A1Medical data miningBiostatisticsDiseasePathway analysis
The present invention comprises: a pathway generation unit 11 that uses a minimum flow algorithm to generate pathways on the basis of property information that indicates the properties of molecules that act on diseases or symptoms, connection information that indicates the connection relationships between molecules, and similarity information that indicates the similarity between molecules; and a score calculation unit 12 that, on the basis of flow values assigned to the individual molecules included on the generated pathways, totals the flow values assigned to one or more molecules connected directly below a single molecule and thereby calculates superiority scores that indicate the strength of the relationships between the molecules and a disease or symptom targeted for drug discovery. On the basis of pathways generated by analysis of intermolecular relationships that go beyond the bounds of known relationships regarding the interactions between pairs of molecules, the present invention effectively utilizes flow values assigned to individual molecules during the analysis to calculate superiority scores and thereby makes it possible to obtain useful knowledge for drug discovery that goes beyond the bounds of known intermolecular interactions.
Owner:FRONTEO INC

Single-cell pathway analysis method developed based on Overlapping Group Lasso

This invention proposes a single-cell pathway analysis method based on Overlapping Group Lasso. The model's logistic form is used to regress gene expression data and cell state for each cell. A Stability Selection algorithm is employed, performing multiple sampling regressions on the data and retaining the pathways with the most stable screening frequency as the final result. The specific steps are as follows: Step 1: Mathematical expression and preprocessing of the input cell gene expression matrix, pathway data, and cell labels; Step 2: Establishing a regression model; Step 3: Solving the regression model; Step 4: Stability selection. The model selects independent variable groups at the pathway level and, based on the characteristics of Overlapping Group Lasso, decomposes the effects of overlapping genes in different genomes, effectively avoiding the influence of overlapping gene effects.
Owner:ACAD OF MATHEMATICS & SYSTEMS SCIENCE - CHINESE ACAD OF SCI

Serum biomarkers for diagnosis and disease activity assessment of takayasu arteritis and application thereof

The application provides serum biomarkers for diagnosing and evaluating the activity of aortitis and application, and relates to the field of disease activity evaluation. The serum biomarkers are serum proteins: HP and ORM1. HP and ORM1 are determined as two new serum biomarkers through comprehensive proteomics analysis; gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis are carried out using a DAVID database; a protein-protein interaction network is constructed using Metascape. A random forest model is trained using a caret package, and a nomogram is visualized using an rms package. Serum samples are obtained, and the serum levels of HP and ORM1 are determined using a commercial ELISA kit; they are significantly related to disease activity, and are involved in inflammation / immune processes in aortitis, so the markers have the potential to serve as an auxiliary tool for monitoring the activity of aortitis.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

Experimental method for verifying effect of anti-fatty liver compound

The invention discloses an experimental method for verifying the effect of an anti-fatty liver compound, which comprises the following steps: S1, constructing a multi-level fatty liver model: respectively constructing a human hepatocyte line fatty degeneration model, an SPF-level mouse high fat diet induced fatty liver model and a db / db gene knockout mouse spontaneous fatty liver model, inducing fatty degeneration through a culture medium containing oleic acid and palmitic acid; s2, gradient treatment of the compound: configuring the anti-fatty liver compound to be verified into four concentration gradients of 0.1 mu mol / L, 1 mu mol / L, 10 mu mol / L and 50 mu mol / L; a multi-dimensional and multi-scale effect evaluation system is formed by integrating lipid metabolism related index detection at a cellular level, serum biochemical indexes at an animal level, liver tissue pathology and protein expression analysis and differential metabolite and pathway analysis at a metabonomics level, so that the improvement effect of a compound on the phenotype of the fatty liver can be intuitively reflected, and the effect of the compound on the phenotype of the fatty liver can be further improved. And the influence on a lipid metabolism molecular mechanism can be deeply revealed.
Owner:SHANXI MEDICAL UNIV

Multi-omics data conjoint analysis and model training method and device, equipment and medium

PendingCN121483386AMedical data miningHealth-index calculationDiseasePathway analysis
The invention relates to the technical field of data processing, in particular to a multi-omics data conjoint analysis and model training method and device, equipment and a medium, and the method comprises the steps: constructing a graph structure based on prior biological knowledge, selecting a center feature from vertexes of the graph structure, and taking other vertexes except the center feature in the graph structure as edge features; constructing a layer network layer based on the graph structure, wherein the first layer is an edge feature with the shortest path from each center feature as a hop in the graph structure; training a preset disease mechanism model by using the training sample to obtain a trained disease mechanism model; a biological pathway transmission layer in the disease mechanism model is used for transmitting the information of the molecular characteristics of the first layer in the molecular characteristics of the sample to the direct connection characteristics in the first layer, gradually transmitting the information of the edge molecular characteristics to the central characteristics of the zero layer, and obtaining the updated central characteristics for disease analysis. According to the technical scheme, path analysis details can be explained.
Owner:THE CHINESE UNIV OF HONG KONG (SHENZHEN)

Maize kernel development regulatory gene ZmRRP45B, its encoded protein, SNP markers, functional markers and their applications

The present invention discloses a corn kernel development regulating gene ZmRRP45B , its encoded protein, SNP marker, molecular marker and its application. This application uses the natural mutant of corn kernels found in the process of field breeding and selection. l168 Cloning of key genes affecting RNA exosome function ZmRRP45B This gene encodes the RNA exosome core subunit RRP45, regulates the development of corn embryo and endosperm, affects the accumulation of grain storage materials, and has important utilization value for improving corn yield and quality; ZmRRP45B The identification of excellent haplotypes and analysis of their utilization pathways provide technical support and excellent germplasm resources for the utilization of the gene. The use of the genes and molecular markers disclosed in the present invention application can facilitate the creation of high-yield or high-quality breeding materials for corn, shorten the breeding cycle of new crop varieties, reduce breeding costs, and improve breeding efficiency.
Owner:HENAN AGRICULTURAL UNIVERSITY

Method for analyzing potential mechanism of EGCG (epigallocatechin gallate) intervening type 2 diabetes mellitus based on network pharmacology

The invention discloses a method for analyzing potential mechanisms of EGCG (epigallocatechin gallate) intervening type 2 diabetes mellitus on the basis of network pharmacology. The molecular mechanism of the EGCG is disclosed by integrating multiple omics technologies. The method comprises the following steps: firstly, predicting an EGCG (epigallocatechin gallate) action target spot by utilizing databases such as PubChem and SwisTargetPrediction, carrying out intersection analysis on the EGCG action target spot and a type II diabetes related pathological target spot, and screening out three key genes, namely ALOX5AP, DGAT1 and PLA2G2A; bulk transcriptome sequencing and single cell transcriptome data are combined, GO / KEGG function enrichment, GSEA / GSVA pathway analysis and five algorithms are adopted to quantify glycolipid metabolism characteristics, and it is clear that key targets participate in lipid metabolism regulation and inflammation signal transduction. Furthermore, a communication network between pancreatic duct cells is analyzed through CellChat, the type of a core cell acted by EGCG is positioned, and the high-affinity interaction of the core cell is confirmed.
Owner:SOUTHWEST FORESTRY UNIVERSITY

Feedback-driven causal contribution node and explainable pathway analysis system

ActiveTWI944781BPathway analysisOriginal data
This invention discloses a feedback-based causal contribution node and explanatory path analysis system applied to a horizontal federated learning architecture involving multiple data providers. Its aim is to quantify the contribution of each data node and its internal data to model performance and causality without sharing the original data, and to provide traceable, visualized, and strategically valuable contribution sharing and data optimization suggestions. The system includes modules for confirming the dataset, confirming contribution rules, and providing feedback and explanatory path analysis. It incorporates methods such as Shapley scores, propensity score, and influence functions to integrate model performance, data heterogeneity, and cost assessment, generating structured contribution quantification and contribution sharing suggestions. The system also features a feedback module that can provide optimization directions and high-contribution suggestions based on data types, promoting fair cooperation and sustainability among nodes, and providing a concrete solution for privacy-preserving artificial intelligence applications.
Owner:TAIWAN MEDICAL IMAGING CO LTD